Paired Liver Biopsies vs Noninvasive Tests as Surrogate Endpoints for Clinical Trials in Metabolic and Alcohol-Related Liver Disease and Alcohol-Related Liver Disease
Clinical Gastroenterology and Hepatology · 2026-05
DOI: 10.1016/j.cgh.2026.04.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Ellen Lyngbeck Jensen und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark; Faculty of Health Sciences, In…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND & AIMS: Drug development for metabolic and alcohol-related liver disease and alcohol-related liver disease is emerging, but designing clinical trials remains challenging due to unknown disease progression rates and a lack of validated surrogate endpoints. We studied fibrosis progression rates and determinants of progression using dual liver biopsies and compared the prognostic performance of 6 noninvasive biomarkers of fibrosis. METHODS: We included patients from 2 randomized controlled trials and 1 cohort study with a history of excessive alcohol intake who underwent paired liver biopsies and noninvasive testing. Fibrosis progression rates were calculated, and associations between changes in histologic and noninvasive biomarkers were analyzed. We used C-statistics to compare how changes in liver biopsy and noninvasive biomarkers after the second liver biopsy predicted hepatic decompensation or death. RESULTS: A total of 164 patients with a median biopsy interval of 1.9 years were included, and the histologic fibrosis progression rate was 0.22 (95% confidence interval, 0.07-0.37) stages per year. The progression rate was increased over 2-fold in patients with active alcohol consumption at baseline compared with abstinent individuals (1 stage every 3 years vs every 8 years). During a median 2.1-year follow-up period after the second biopsy, 21 patients decompensated or died (13%). The delta value (change from baseline to second biopsy) showed that histologic fibrosis stage and noninvasive biomarkers equally predicted adverse outcomes: LiverPRO (0.78), pro-collagen type III N-terminal propeptide (0.72), histologic fibrosis stage (0.70), Fibrosis-4 index (0.68), transient elastography (0.66), Agile 3+ (0.75), and Enhanced Liver Fibrosis test (0.64). CONCLUSIONS: Active alcohol consumption determines fibrosis progression in alcohol-related liver disease and metabolic and alcohol-related liver disease. Noninvasive biomarkers are promising surrogate markers for understanding disease dynamics and monitoring in clinical trials in alcohol-related liver disease and metabolic and alcohol-related liver disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark; Faculty of Health Sciences, Institute of Clinical Research, University of Southern Denmark, Odense,…
- Department of Pathology, Odense University Hospital, Odense, Denmark.
- Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark.
- Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark; Department of Gastroenterology and Hepatology, Herlev Hospital, Denmark.
- Nordic Bioscience A/S, Biomarkers & Research, Herlev, Denmark.
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Zitieren
APA
Jensen, E. L., Thiele, M., Torp, N., Johansen, S., Hansen, J. K., Sørensen, M. D., Hansen, C. D., Hovland, M., Andersen, M. L., Semmler, G., Thorhauge, K., Schnefeld, H. L., Villesen, I., Bech, K. T., Andersen, P., Leeming, D. J., Karsdal, M., Lindvig, K. P., Hansen, T., …, & MicrobLiver Consortia (2026). Paired Liver Biopsies vs Noninvasive Tests as Surrogate Endpoints for Clinical Trials in Metabolic and Alcohol-Related Liver Disease and Alcohol-Related Liver Disease. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.04.027
Vancouver
Jensen EL, Thiele M, Torp N, Johansen S, Hansen JK, Sørensen MD, et al. Paired Liver Biopsies vs Noninvasive Tests as Surrogate Endpoints for Clinical Trials in Metabolic and Alcohol-Related Liver Disease and Alcohol-Related Liver Disease. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.04.027
BibTeX
@article{Jensen2026,
author = {Jensen, Ellen Lyngbeck and Thiele, Maja and Torp, Nikolaj and Johansen, Stine and Hansen, Johanne Kragh and Sørensen, Mia Dahl and Hansen, Camilla Dalby and Hovland, Mathilde and Andersen, Mette Lehmann and Semmler, Georg and Thorhauge, Katrine and Schnefeld, Helle Lindholm and Villesen, Ida and Bech, Katrine Tholstrup and Andersen, Peter and Leeming, Diana Julie and Karsdal, Morten and Lindvig, Katrine Prier and Hansen, Torben and Krag, Aleksander and Detlefsen, Sönke and Israelsen, Mads and GALAXY, GALAXY and MicrobLiver Consortia, MicrobLiver Consortia},
title = {Paired Liver Biopsies vs Noninvasive Tests as Surrogate Endpoints for Clinical Trials in Metabolic and Alcohol-Related Liver Disease and Alcohol-Related Liver Disease},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.04.027}
}
EUVIMED